Research programme: anti-factor XI monoclonal antibodies - Novartis

Drug Profile

Research programme: anti-factor XI monoclonal antibodies - Novartis

Alternative Names: NOV 1090; NOV 1401

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 29 Dec 2016 Preclinical trials in Thrombosis in Switzerland (Parenteral) before December 2016
  • 29 Dec 2016 Novartis has a published patent application with World Intellectual Property Organization for anti-factor XI antibodies or fragments for Thrombosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top